Neogen price target cut to $60 from $67 at Craig-Hallum

Craig-Hallum analyst Kevin Ellich maintained a Hold rating on Neogen after the company reported “mixed” Q2 results. In a research note to investors, Ellich says that while Neogen’s international operations continues to drive solid growth and the company has a highly diversified product mix, he maintains his rating and lowers his price target to $60 due to valuation and potential near-term headwinds from trade issues with China and pockets of continued weakness in the U.S. livestock market.
https://thefly.com/landingPageNews.php?id=2840595